Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | CPI-444 |
Trade Name | |
Synonyms | Ciforadenant|V81444|CPI 444|CPI444 |
Drug Descriptions |
Ciforadenant (CPI-444) binds to and inhibits A2A (ADORA2A) on immune cells, which may increase anti-tumor immune response and inhibit tumor growth by blocking binding of the immunosuppressive metabolite, adenosine (PMID: 29923026, PMID: 30131376). |
DrugClasses | Adenosine Targeting 23 |
CAS Registry Number | 1202402-40-1 |
NCIT ID | C125659 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Atezolizumab + CPI-444 | Atezolizumab CPI-444 | 0 | 2 |
CPI-006 + CPI-444 | CPI-006 CPI-444 | 0 | 1 |
CPI-444 | CPI-444 | 0 | 2 |
CPI-444 + Daratumumab | CPI-444 Daratumumab | 0 | 1 |
CPI-444 + Ipilimumab + Nivolumab | CPI-444 Ipilimumab Nivolumab | 0 | 1 |